![Randomized trial assessing the safety and efficacy of sitagliptin in Chinese patients with type 2 diabetes mellitus inadequately controlled on sulfonylurea alone or combined with metformin - Ba - 2017 - Journal Randomized trial assessing the safety and efficacy of sitagliptin in Chinese patients with type 2 diabetes mellitus inadequately controlled on sulfonylurea alone or combined with metformin - Ba - 2017 - Journal](https://onlinelibrary.wiley.com/cms/asset/47e60953-f2f3-418a-a443-deead55b4346/jdb12456-fig-0002-m.jpg)
Randomized trial assessing the safety and efficacy of sitagliptin in Chinese patients with type 2 diabetes mellitus inadequately controlled on sulfonylurea alone or combined with metformin - Ba - 2017 - Journal
![Sitagliptin Compared with Thiazolidinediones as a Third-Line Oral Antihyperglycemic Agent in Type 2 Diabetes Mellitus - Endocrine Practice Sitagliptin Compared with Thiazolidinediones as a Third-Line Oral Antihyperglycemic Agent in Type 2 Diabetes Mellitus - Endocrine Practice](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/asset/c2beda9e-d469-49a6-a4e6-624d0138e045/gr1.jpg)
Sitagliptin Compared with Thiazolidinediones as a Third-Line Oral Antihyperglycemic Agent in Type 2 Diabetes Mellitus - Endocrine Practice
![Incretin drugs in diabetic kidney disease: biological mechanisms and clinical evidence | Nature Reviews Nephrology Incretin drugs in diabetic kidney disease: biological mechanisms and clinical evidence | Nature Reviews Nephrology](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41581-020-00367-2/MediaObjects/41581_2020_367_Fig1_HTML.png)
Incretin drugs in diabetic kidney disease: biological mechanisms and clinical evidence | Nature Reviews Nephrology
![Sitagliptin for type 2 diabetes mellitus | DPP 4 inhibitor | Mechanism, precautions & side effects - YouTube Sitagliptin for type 2 diabetes mellitus | DPP 4 inhibitor | Mechanism, precautions & side effects - YouTube](https://i.ytimg.com/vi/xAWCneDnfso/maxresdefault.jpg)
Sitagliptin for type 2 diabetes mellitus | DPP 4 inhibitor | Mechanism, precautions & side effects - YouTube
![Frontiers | DPP4 and ACE2 in Diabetes and COVID-19: Therapeutic Targets for Cardiovascular Complications? | Pharmacology Frontiers | DPP4 and ACE2 in Diabetes and COVID-19: Therapeutic Targets for Cardiovascular Complications? | Pharmacology](https://www.frontiersin.org/files/Articles/569989/fphar-11-01161-HTML/image_m/fphar-11-01161-g001.jpg)
Frontiers | DPP4 and ACE2 in Diabetes and COVID-19: Therapeutic Targets for Cardiovascular Complications? | Pharmacology
![Sitagliptin vs. pioglitazone as add-on treatments in patients with uncontrolled type 2 diabetes on the maximal dose of metformin plus sulfonylurea | SpringerLink Sitagliptin vs. pioglitazone as add-on treatments in patients with uncontrolled type 2 diabetes on the maximal dose of metformin plus sulfonylurea | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs40618-018-0991-0/MediaObjects/40618_2018_991_Fig1_HTML.png)
Sitagliptin vs. pioglitazone as add-on treatments in patients with uncontrolled type 2 diabetes on the maximal dose of metformin plus sulfonylurea | SpringerLink
![Cardiovascular effects of sitagliptin – An anti‐diabetes medicine - Zhou - 2018 - Clinical and Experimental Pharmacology and Physiology - Wiley Online Library Cardiovascular effects of sitagliptin – An anti‐diabetes medicine - Zhou - 2018 - Clinical and Experimental Pharmacology and Physiology - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/4d8ecd1a-584a-4520-be0d-f59173ccd63a/cep12953-fig-0001-m.jpg)
Cardiovascular effects of sitagliptin – An anti‐diabetes medicine - Zhou - 2018 - Clinical and Experimental Pharmacology and Physiology - Wiley Online Library
![Effect of sitagliptin on blood glucose control in patients with type 2 diabetes mellitus who are treatment naive or poorly responsive to existing antidiabetic drugs: the JAMP study | BMC Endocrine Disorders Effect of sitagliptin on blood glucose control in patients with type 2 diabetes mellitus who are treatment naive or poorly responsive to existing antidiabetic drugs: the JAMP study | BMC Endocrine Disorders](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs12902-016-0149-z/MediaObjects/12902_2016_149_Fig2_HTML.gif)
Effect of sitagliptin on blood glucose control in patients with type 2 diabetes mellitus who are treatment naive or poorly responsive to existing antidiabetic drugs: the JAMP study | BMC Endocrine Disorders
![Dipeptidyl peptidase-4 inhibitor Glucagon-like peptide-1 receptor agonist Liraglutide Dulaglutide, others, angle, text, pharmaceutical Drug png | PNGWing Dipeptidyl peptidase-4 inhibitor Glucagon-like peptide-1 receptor agonist Liraglutide Dulaglutide, others, angle, text, pharmaceutical Drug png | PNGWing](https://w7.pngwing.com/pngs/475/613/png-transparent-dipeptidyl-peptidase-4-inhibitor-glucagon-like-peptide-1-receptor-agonist-liraglutide-dulaglutide-others-angle-text-pharmaceutical-drug.png)
Dipeptidyl peptidase-4 inhibitor Glucagon-like peptide-1 receptor agonist Liraglutide Dulaglutide, others, angle, text, pharmaceutical Drug png | PNGWing
![Dipeptidyl peptidase 4 inhibitors in the treatment of type 2 diabetes mellitus | Nature Reviews Endocrinology Dipeptidyl peptidase 4 inhibitors in the treatment of type 2 diabetes mellitus | Nature Reviews Endocrinology](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41574-020-0399-8/MediaObjects/41574_2020_399_Fig1_HTML.png)
Dipeptidyl peptidase 4 inhibitors in the treatment of type 2 diabetes mellitus | Nature Reviews Endocrinology
![Continued) Oral diabetes medications: mechanism of action, side effects. | Download Scientific Diagram Continued) Oral diabetes medications: mechanism of action, side effects. | Download Scientific Diagram](https://www.researchgate.net/profile/Alyson-Myers-4/publication/322237224/figure/tbl3/AS:1045262256582657@1626221350625/Continued-Oral-diabetes-medications-mechanism-of-action-side-effects.png)
Continued) Oral diabetes medications: mechanism of action, side effects. | Download Scientific Diagram
![The role of dipeptidylpeptidase-4 inhibitors in management of cardiovascular disease in diabetes; focus on linagliptin | Cardiovascular Diabetology | Full Text The role of dipeptidylpeptidase-4 inhibitors in management of cardiovascular disease in diabetes; focus on linagliptin | Cardiovascular Diabetology | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs12933-018-0704-1/MediaObjects/12933_2018_704_Fig2_HTML.gif)